{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T20:14:56Z","timestamp":1792872896684,"version":"4.5.0"},"reference-count":56,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100003593","name":"Conselho Nacional de Desenvolvimento Cient\u00edfico e Tecnol\u00f3gico","doi-asserted-by":"publisher","award":["310987\/2018-0"],"award-info":[{"award-number":["310987\/2018-0"]}],"id":[{"id":"10.13039\/501100003593","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmacology"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1016\/j.ejphar.2023.175590","type":"journal-article","created":{"date-parts":[[2023,2,10]],"date-time":"2023-02-10T16:43:58Z","timestamp":1676047438000},"page":"175590","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":52,"special_numbering":"C","title":["Use of histone methyltransferase inhibitors in cancer treatment: A systematic review"],"prefix":"10.1016","volume":"944","author":[{"given":"Ludimila Leite","family":"Marzochi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline Izak","family":"Cuzziol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos Henrique Viesi Do","family":"Nascimento Filho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juliana Amorim","family":"dos Santos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M\u00e1rcia Maria Urbanin","family":"Castanhole-Nunes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c9rika Cristina","family":"Pavarino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eliete Neves Silva","family":"Guerra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2622-4673","authenticated-orcid":false,"given":"Eny Maria","family":"Goloni-Bertollo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejphar.2023.175590_bib1","doi-asserted-by":"crossref","DOI":"10.1038\/srep34984","article-title":"Structural insights into conformational stability of both wild-type and mutant EZH2 receptor","volume":"6","author":"Aier","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejphar.2023.175590_bib2","doi-asserted-by":"crossref","DOI":"10.3389\/fgene.2022.864612","article-title":"Histone methyltransferase DOT1L as a promising epigenetic target for treatment of solid tumors","volume":"13","author":"Alexandrova","year":"2022","journal-title":"Front. Genet."},{"issue":"14","key":"10.1016\/j.ejphar.2023.175590_bib3","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1056\/NEJMe1706154","article-title":"Which anti-CD20 antibody is better in follicular lymphoma?","volume":"377","author":"Armitage","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.ejphar.2023.175590_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbagrm.2022.194840","article-title":"Chemical biology and pharmacology of histone lysine methylation inhibitors","volume":"1865","author":"Barghout","year":"2022","journal-title":"Biochim. Biophys. Acta. Gene. Regul. Mech."},{"issue":"44","key":"10.1016\/j.ejphar.2023.175590_bib5","doi-asserted-by":"crossref","first-page":"27365","DOI":"10.1073\/pnas.2001075117","article-title":"DOT1L-controlled cell-fate determination and transcription elongation are independent of H3K79 methylation","volume":"117","author":"Cao","year":"2020","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.ejphar.2023.175590_bib6","series-title":"Proceedings of the American Association for Cancer Research Annual Meeting 2022","article-title":"HH2853 is a selective small molecular dual inhibitor of EZH1\/2 with potent anti-tumor activities [abstract]","author":"Chen","year":"2022"},{"issue":"30","key":"10.1016\/j.ejphar.2023.175590_bib7","doi-asserted-by":"crossref","first-page":"3565","DOI":"10.1200\/JCO.20.01501","article-title":"Diffuse large B-cell lymphoma's new genomics: the bridge and the chasm","volume":"38","author":"Crombie","year":"2020","journal-title":"J. Clin. Oncol."},{"issue":"6","key":"10.1016\/j.ejphar.2023.175590_bib8","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1182\/blood-2013-04-497644","article-title":"Potent inhibition of DOT1L as treatment of MLL-fusion leukemia","volume":"122","author":"Daigle","year":"2013","journal-title":"Blood"},{"issue":"17","key":"10.1016\/j.ejphar.2023.175590_bib9","doi-asserted-by":"crossref","first-page":"2626","DOI":"10.3390\/cells11172626","article-title":"Beyond SMARCB1 loss: recent insights into the pathobiology of epithelioid sarcoma","volume":"11","author":"Del Savio","year":"2022","journal-title":"Cells"},{"key":"10.1016\/j.ejphar.2023.175590_bib10","article-title":"Study on pharmacokinetic interactions between SHR2554 and itraconazole in healthy subjects: a single-center, open-label phase I trial","author":"Deng","year":"2022","journal-title":"Cancer Med."},{"issue":"1","key":"10.1016\/j.ejphar.2023.175590_bib11","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1186\/s13045-020-00937-8","article-title":"EZH2: a novel target for cancer treatment","volume":"13","author":"Duan","year":"2020","journal-title":"J. Hematol. Oncol."},{"issue":"1","key":"10.1016\/j.ejphar.2023.175590_bib12","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1080\/0284186X.2019.1659514","article-title":"Epithelioid sarcoma: half a century later","volume":"59","author":"Elsamna","year":"2020","journal-title":"Acta Oncol."},{"key":"10.1016\/j.ejphar.2023.175590_bib13","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s40364-018-0122-2","article-title":"Epigenetic regulation of cancer progression by EZH2: from biological insights to therapeutic potential","volume":"6","author":"Gan","year":"2018","journal-title":"Biomark. Res."},{"issue":"1","key":"10.1016\/j.ejphar.2023.175590_bib14","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1186\/s13148-019-0776-0","article-title":"The timeline of epigenetic drug discovery: from reality to dreams","volume":"11","author":"Ganesan","year":"2019","journal-title":"Clin. Epigenet."},{"issue":"5","key":"10.1016\/j.ejphar.2023.175590_bib15","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1038\/onc.2015.114","article-title":"Development of secondary mutations in wild-type and mutant EZH2 alleles cooperates to confer resistance to EZH2 inhibitors","volume":"35","author":"Gibaja","year":"2016","journal-title":"Oncogene"},{"key":"10.1016\/j.ejphar.2023.175590_bib16","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.mrrev.2017.09.003","article-title":"Histone methylation and the DNA damage response","volume":"780","author":"Gong","year":"2019","journal-title":"Mutat. Res. Rev. Mutat. Res."},{"issue":"11","key":"10.1016\/j.ejphar.2023.175590_bib17","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1016\/S1470-2045(20)30451-4","article-title":"Tazemetostat in advanced epithelioid sarcoma with loss of INI1\/SMARCB1: an international, open-label, phase 2 basket study","volume":"21","author":"Gounder","year":"2020","journal-title":"Lancet Oncol."},{"issue":"7","key":"10.1016\/j.ejphar.2023.175590_bib18","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1080\/10428194.2018.1430795","article-title":"Enhancer of zeste homolog 2 (EZH2) inhibitors","volume":"59","author":"Gulati","year":"2018","journal-title":"Leuk. Lymphoma"},{"issue":"12","key":"10.1016\/j.ejphar.2023.175590_bib19","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1158\/2159-8290.CD-18-0804","article-title":"Integrative molecular characterization of malignant pleural mesothelioma","volume":"8","author":"Hmeljak","year":"2018","journal-title":"Cancer Discov."},{"issue":"5","key":"10.1016\/j.ejphar.2023.175590_bib20","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/S1470-2045(18)30145-1","article-title":"Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumors: a first-in-human, open-label, phase 1 study","volume":"19","author":"Italiano","year":"2018","journal-title":"Lancet Oncol."},{"issue":"9","key":"10.1016\/j.ejphar.2023.175590_bib21","doi-asserted-by":"crossref","first-page":"3627","DOI":"10.1111\/cas.15040","article-title":"Phase II study of tazemetostat for relapsed or refractory B-cell non-Hodgkin lymphoma with EZH2 mutation in Japan","volume":"112","author":"Izutsu","year":"2021","journal-title":"Cancer Sci."},{"issue":"20","key":"10.1016\/j.ejphar.2023.175590_bib22","doi-asserted-by":"crossref","DOI":"10.3390\/ijms232012323","article-title":"PRMT7 inhibitor SGC8158 enhances doxorubicin-induced DNA damage and its cytotoxicity","volume":"23","author":"Jeong","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejphar.2023.175590_bib23","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/1476-4598-5-4","article-title":"The tumor suppressor DAL-1\/4.1B and protein methylation cooperate in inducing apoptosis in MCF-7 breast cancer cells","volume":"5","author":"Jiang","year":"2006","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.ejphar.2023.175590_bib24","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.gde.2017.03.015","article-title":"The promise of epigenetic therapy: reprogramming the cancer epigenome","volume":"42","author":"Kelly","year":"2017","journal-title":"Curr. Opin. Genet. Dev."},{"issue":"2","key":"10.1016\/j.ejphar.2023.175590_bib25","first-page":"161","article-title":"Emerging targets in cancer drug resistance. Cancer","volume":"2","author":"Kumar","year":"2019","journal-title":"Drug Res."},{"issue":"11","key":"10.1016\/j.ejphar.2023.175590_bib26","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1038\/nm.3947","article-title":"Loss of BAP1 function leads to EZH2-dependent transformation","volume":"21","author":"LaFave","year":"2015","journal-title":"Nat. Med."},{"issue":"7427","key":"10.1016\/j.ejphar.2023.175590_bib57","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1038\/nature11606","article-title":"EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations","volume":"492","author":"McCabe","year":"2012","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.ejphar.2023.175590_bib27","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1038\/s41392-022-01240-3","article-title":"Discovery of IHMT-337 as a potent irreversible EZH2 inhibitor targeting CDK4 transcription for malignancies","volume":"8","author":"Mei","year":"2023","journal-title":"Signal Transduct. Targeted Ther."},{"issue":"12","key":"10.1016\/j.ejphar.2023.175590_bib28","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1080\/15592294.2019.1640546","article-title":"Epidrugs: targeting epigenetic marks in cancer treatment","volume":"14","author":"Miranda Furtado","year":"2019","journal-title":"Epigenetics"},{"key":"10.1016\/j.ejphar.2023.175590_bib29","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2020.605386","article-title":"Epidrug repurposing: discovering new faces of old acquaintances in cancer therapy","volume":"10","author":"Montalvo-Casimiro","year":"2020","journal-title":"Front. Oncol."},{"issue":"11","key":"10.1016\/j.ejphar.2023.175590_bib30","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1016\/S1470-2045(20)30441-1","article-title":"Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial","volume":"21","author":"Morschhauser","year":"2020","journal-title":"Lancet Oncol."},{"issue":"3","key":"10.1016\/j.ejphar.2023.175590_bib56","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1111\/cas.14822","article-title":"Phase 1 study of tazemetostat in Japanese patients with relapsed or refractory B-cell lymphoma","volume":"112","author":"Munakata","year":"2021","journal-title":"Cancer Sci."},{"issue":"1","key":"10.1016\/j.ejphar.2023.175590_bib32","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1186\/s12943-022-01602-z","article-title":"PRMT7: a survive-or-die switch in cancer stem cells","volume":"21","author":"Nicot","year":"2022","journal-title":"Mol. Cancer"},{"issue":"9","key":"10.1016\/j.ejphar.2023.175590_bib33","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1038\/s41580-022-00483-w","article-title":"Establishment of H3K9-methylated heterochromatin and its functions in tissue differentiation and maintenance","volume":"23","author":"Padeken","year":"2022","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.ejphar.2023.175590_bib34","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"issue":"7","key":"10.1016\/j.ejphar.2023.175590_bib35","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/j.clml.2021.12.014","article-title":"Combination of atezolizumab and tazemetostat in patients with relapsed\/refractory diffuse large B-cell lymphoma: results from a phase Ib study","volume":"22","author":"Palomba","year":"2022","journal-title":"Clin. Lymphoma, Myeloma & Leukemia"},{"issue":"3","key":"10.1016\/j.ejphar.2023.175590_bib36","doi-asserted-by":"crossref","DOI":"10.1002\/jbt.22674","article-title":"Targeting H3K9 methyltransferase G9a and its related molecule GLP as a potential therapeutic strategy for cancer","volume":"35","author":"Rahman","year":"2021","journal-title":"J. Biochem. Mol. Toxicol."},{"issue":"13","key":"10.1016\/j.ejphar.2023.175590_bib37","doi-asserted-by":"crossref","first-page":"3145","DOI":"10.1158\/1078-0432.CCR-19-3741","article-title":"A LYSA phase Ib study of tazemetostat (EPZ-6438) plus R-CHOP in patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL) with poor prognosis features","volume":"26","author":"Sarkozy","year":"2020","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.ejphar.2023.175590_bib38","doi-asserted-by":"crossref","first-page":"54","DOI":"10.3348\/kjr.2017.18.1.54","article-title":"Diffuse large B-cell lymphoma in the era of precision oncology: how imaging is helpful","volume":"18","author":"Shah","year":"2017","journal-title":"Korean J. Radiol."},{"issue":"47","key":"10.1016\/j.ejphar.2023.175590_bib39","doi-asserted-by":"crossref","first-page":"7761","DOI":"10.1038\/sj.onc.1208057","article-title":"DAL-1\/4.1B tumor suppressor interacts with protein arginine N-methyltransferase 3 (PRMT3) and inhibits its ability to methylate substrates in vitro and in vivo","volume":"23","author":"Singh","year":"2004","journal-title":"Oncogene"},{"issue":"7","key":"10.1016\/j.ejphar.2023.175590_bib40","doi-asserted-by":"crossref","first-page":"e493","DOI":"10.1016\/S2352-3026(22)00134-X","article-title":"SHR2554, an EZH2 inhibitor, in relapsed or refractory mature lymphoid neoplasms: a first-in-human, dose-escalation, dose-expansion, and clinical expansion phase 1 trial","volume":"9","author":"Song","year":"2022","journal-title":"Lancet. Haematol."},{"issue":"4","key":"10.1016\/j.ejphar.2023.175590_bib41","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1007\/s12017-022-08702-5","article-title":"G9a\/EHMT2 is a potential prognostic biomarker and molecular target in SHH medulloblastoma","volume":"24","author":"Souza","year":"2022","journal-title":"NeuroMolecular Med."},{"issue":"24","key":"10.1016\/j.ejphar.2023.175590_bib42","doi-asserted-by":"crossref","first-page":"2661","DOI":"10.1182\/blood-2017-12-818948","article-title":"The DOT1L inhibitor pinometostat reduces H3K79 methylation and has modest clinical activity in adult acute leukemia","volume":"131","author":"Stein","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.ejphar.2023.175590_bib43","doi-asserted-by":"crossref","first-page":"i4919","DOI":"10.1136\/bmj.i4919","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions","volume":"355","author":"Sterne","year":"2016","journal-title":"Br. Med. J."},{"issue":"3","key":"10.1016\/j.ejphar.2023.175590_bib44","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1158\/0008-5472.CAN-20-2906","article-title":"Histone methyltransferase SETDB1: a common denominator of tumorigenesis with therapeutic potential","volume":"81","author":"Strepkos","year":"2021","journal-title":"Cancer Res."},{"issue":"3","key":"10.1016\/j.ejphar.2023.175590_bib45","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA A Cancer J. Clin."},{"key":"10.1016\/j.ejphar.2023.175590_bib46","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.bbrc.2022.11.102","article-title":"The role of H3K9me3 in oral squamous cell carcinoma","volume":"640","author":"Tanaka","year":"2023","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"15","key":"10.1016\/j.ejphar.2023.175590_bib47","doi-asserted-by":"crossref","first-page":"2917","DOI":"10.1007\/s00018-019-03145-x","article-title":"Protein arginine methyltransferases: insights into the enzyme structure and mechanism at the atomic level","volume":"76","author":"Tewary","year":"2019","journal-title":"Cell. Mol. Life Sci."},{"issue":"1","key":"10.1016\/j.ejphar.2023.175590_bib48","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/s13148-019-0644-y","article-title":"Emerging roles of H3K9me3, SETDB1 and SETDB2 in therapy-induced cellular reprogramming","volume":"11","author":"Torrano","year":"2019","journal-title":"Clin. Epigenet."},{"issue":"17","key":"10.1016\/j.ejphar.2023.175590_bib49","doi-asserted-by":"crossref","first-page":"4249","DOI":"10.3390\/cancers13174249","article-title":"The synergistic anti-tumor activity of EZH2 inhibitor SHR2554 and HDAC inhibitor chidamide through ORC1 reduction of DNA replication process in diffuse large B cell lymphoma","volume":"13","author":"Wang","year":"2021","journal-title":"Cancers"},{"issue":"21","key":"10.1016\/j.ejphar.2023.175590_bib50","doi-asserted-by":"crossref","first-page":"9429","DOI":"10.1021\/acs.jmedchem.8b00598","article-title":"Protein arginine methyltransferase 5 (PRMT5) as an anticancer target and its inhibitor discovery","volume":"61","author":"Wang","year":"2018","journal-title":"J. Med. Chem."},{"issue":"7","key":"10.1016\/j.ejphar.2023.175590_bib51","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1038\/s41573-021-00159-8","article-title":"Protein arginine methylation: from enigmatic functions to therapeutic targeting","volume":"20","author":"Wu","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"issue":"7","key":"10.1016\/j.ejphar.2023.175590_bib52","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1038\/s41573-021-00159-8","article-title":"Protein arginine methylation: from enigmatic functions to therapeutic targeting","volume":"20","author":"Wu","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"issue":"1","key":"10.1016\/j.ejphar.2023.175590_bib53","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/nrc3409","article-title":"Protein arginine methyltransferases and cancer","volume":"13","author":"Yang","year":"2013","journal-title":"Nat. Rev. Cancer"},{"issue":"24","key":"10.1016\/j.ejphar.2023.175590_bib54","doi-asserted-by":"crossref","first-page":"7331","DOI":"10.1158\/1078-0432.CCR-18-4121","article-title":"Phase I study of the novel enhancer of zeste homolog 2 (EZH2) inhibitor GSK2816126 in patients with advanced hematologic and solid tumors","volume":"25","author":"Yap","year":"2019","journal-title":"Clin. Cancer Res."},{"issue":"6","key":"10.1016\/j.ejphar.2023.175590_bib55","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1016\/S1470-2045(22)00277-7","article-title":"EZH2 inhibitor tazemetostat in patients with relapsed or refractory, BAP1-inactivated malignant pleural mesothelioma: a multicentre, open-label, phase 2 study","volume":"23","author":"Zauderer","year":"2022","journal-title":"Lancet Oncol."}],"container-title":["European Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299923001012?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299923001012?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T04:22:37Z","timestamp":1762143757000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014299923001012"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4]]},"references-count":56,"alternative-id":["S0014299923001012"],"URL":"https:\/\/doi.org\/10.1016\/j.ejphar.2023.175590","relation":{},"ISSN":["0014-2999"],"issn-type":[{"value":"0014-2999","type":"print"}],"subject":[],"published":{"date-parts":[[2023,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Use of histone methyltransferase inhibitors in cancer treatment: A systematic review","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejphar.2023.175590","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"175590"}}